Evolus (EOLS) Operating Income (2017 - 2026)
Evolus (EOLS) posted Operating Income of -$6.8 million for Q1 2026, down 262.27% on a QoQ basis from $4.2 million in Q4 2025, and up 54.86% year-over-year from -$4.4 million in Q1 2025.
Evolus (EOLS) Operating Income (2017 - 2026) Analysis & Trends
Evolus' Operating Income history runs 10 years deep, the most recent figure standing at -$6.8 million for Q1 2026.
- Quarterly Operating Income rose 54.86% year-over-year to -$6.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$24.3 million (up 40.14% YoY) and the FY2025 annual result came in at -$32.7 million, up 5.08% from the prior year.
- Operating Income was -$6.8 million for Q1 2026 at Evolus, down from $4.2 million in the prior quarter.
- Across five years, Operating Income topped out at $4.2 million in Q4 2025 and bottomed at -$21.3 million in Q2 2022.
- A 5-year average of -$11.1 million and a median of -$11.5 million in 2025 frame the typical range for Operating Income.
- Annual changes were most pronounced in 2022 — Operating Income plunged 292.47% — and 2025, when it surged 282.37%.
- Evolus' Operating Income stood at -$10.6 million in 2022, then advanced by 18.82% to -$8.6 million in 2023, then surged by 73.2% to -$2.3 million in 2024, then jumped by 282.37% to $4.2 million in 2025, then plunged by 262.27% to -$6.8 million in 2026.
- Business Quant data shows EOLS's Operating Income at -$6.8 million in Q1 2026, $4.2 million in Q4 2025, and -$11.5 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 652.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 833.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -2.65 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 325.80 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -79.70 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 193.40 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 291.00 Mn |
| 10 | Evolus | 390.47 Mn | 340.68 Mn | 48.90 Mn | -6.85 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -6.85 Mn |
| Dec 31, 2025 | 4.22 Mn |
| Sep 30, 2025 | -11.50 Mn |
| Jun 30, 2025 | -10.21 Mn |
| Mar 31, 2025 | -15.17 Mn |
| Dec 31, 2024 | -2.31 Mn |
| Sep 30, 2024 | -15.47 Mn |
| Jun 30, 2024 | -7.70 Mn |
| Mar 31, 2024 | -8.92 Mn |
| Dec 31, 2023 | -8.64 Mn |
| Sep 30, 2023 | -13.44 Mn |
| Jun 30, 2023 | -15.12 Mn |
| Mar 31, 2023 | -12.04 Mn |
| Dec 31, 2022 | -10.64 Mn |
| Sep 30, 2022 | -17.90 Mn |
| Jun 30, 2022 | -21.35 Mn |
| Mar 31, 2022 | -15.45 Mn |
| Dec 31, 2021 | -18.03 Mn |
| Sep 30, 2021 | -19.11 Mn |
| Jun 30, 2021 | -15.29 Mn |